Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03783377




Registration number
NCT03783377
Ethics application status
Date submitted
19/12/2018
Date registered
21/12/2018
Date last updated
3/03/2021

Titles & IDs
Public title
Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)
Scientific title
A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-APOC3 in Adult Healthy Volunteers as Well as in Severely Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome
Secondary ID [1] 0 0
AROAPOC31001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hypertriglyceridemia 0 0
Familial Chylomicronemia 0 0
Condition category
Condition code
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders
Metabolic and Endocrine 0 0 0 0
Other metabolic disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - ARO-APOC3
Treatment: Drugs - sterile normal saline (0.9% NaCl)

Experimental: ARO-APOC3 -

Placebo Comparator: Placebo -


Treatment: Drugs: ARO-APOC3
single or multiple doses of ARO-APOC3 by subcutaneous (sc) injections

Treatment: Drugs: sterile normal saline (0.9% NaCl)
calculated volume to match active treatment
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants with Adverse Events (AEs) Possibly or Probably Related to Treatment
Timepoint [1] 0 0
Up to Day 113 (+/- 3 days)
Secondary outcome [1] 0 0
Pharmacokinetics (PK) of ARO-APOC3 in Normal Healthy Volunteers (NHVs): Maximum Observed Plasma Concentration (Cmax)
Timepoint [1] 0 0
Single dose phase: Up to 48 hours post-dose
Secondary outcome [2] 0 0
PK of ARO-APOC3 in NHVs: Time to Maximum Plasma Concentration (Tmax)
Timepoint [2] 0 0
Single dose phase: Up to 48 hours post-dose
Secondary outcome [3] 0 0
PK of ARO-APOC3 in NHVs: Terminal Elimination Half-Life (t1/2)
Timepoint [3] 0 0
Single dose phase: Up to 48 hours post-dose
Secondary outcome [4] 0 0
PK of ARO-APOC3 in NHVs: Area Under the Plasma Concentration Versus Time Curve From Zero to 24 Hours (AUC0-24)
Timepoint [4] 0 0
Single dose phase: Up to 48 hours post-dose
Secondary outcome [5] 0 0
PK of ARO-APOC3 in NHVs: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUCinf)
Timepoint [5] 0 0
Single dose phase: Up to 48 hours post-dose
Secondary outcome [6] 0 0
Reduction in Fasting Serum APOC3 from Pre-Dose Baseline
Timepoint [6] 0 0
Up to Day 113 (+/- 3 days)

Eligibility
Key inclusion criteria
- Women of childbearing potential must have a negative pregnancy test, cannot be
breastfeeding and must be willing to use contraception

- Willing to provide written informed consent and to comply with study requirements

- Normal electrocardiogram (ECG) at screening

- Hypertriglyceridemic patients must have a history of fasting serum triglycerides of at
least 300 mg/dL (3.38 mmol/L) at screening or verifiable diagnosis of FCS
Minimum age
18 Years
Maximum age
70 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
- Clinically significant health concerns

- Regular use of alcohol within one month prior to Screening

- Use of an investigational agent or device within 30 days prior to dosing or current
participation in an investigational study

- Recent use of illicit drugs

- Use of more than two tobacco/nicotine containing or cannabis products per month within
6 months prior to drug administration (applicable only to Normal Healthy Volunteers)

Note: additional inclusion/exclusion criteria may apply, per protocol

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
8/03/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
11/02/2021
Sample size
Target
Accrual to date
Final
112
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,WA
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [2] 0 0
University of the Sunshine Coast Clinical Trial Centre - Sippy Downs
Recruitment hospital [3] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [4] 0 0
Linear Clinical Research - Perth
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
- Sippy Downs
Recruitment postcode(s) [3] 0 0
5000 - Adelaide
Recruitment postcode(s) [4] 0 0
6009 - Perth
Recruitment outside Australia
Country [1] 0 0
Canada
State/province [1] 0 0
Ontario
Country [2] 0 0
Canada
State/province [2] 0 0
Quebec
Country [3] 0 0
New Zealand
State/province [3] 0 0
Auckland
Country [4] 0 0
New Zealand
State/province [4] 0 0
Christchurch

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Arrowhead Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and
pharmacodynamics of single- and multiple doses of ARO-APOC3 in healthy adult volunteers and
in patients with severe hypertriglyceridemia and familial chylomicronemia syndrome (FCS).
Trial website
https://clinicaltrials.gov/ct2/show/NCT03783377
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03783377